• Home
  • Study Details
By physician referral or invitation only

Bladder cancer study with EG-70

This study will evaluate the safety and tolerability of EG 70, a gene therapy, which is given inside the bladder, and its effectiveness on eliminating bladder tumors in patients with NMIBC who have failed BCG therapy and have been recommended to have their bladder removed. Giving the study drug inside the bladder is to expose cells in the lining of the bladder, including your cancerous cells, to genes that may cause an immune response inside the bladder and kill the tumor cells.

Age & Gender

  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study is recruiting by invitation only.

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Marc Bjurlin
Urology

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Bladder)

IRB Number

22-0761

ClinicalTrials.gov

NCT04752722

Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research